Michael P. Silvon
Direttore/Membro del Consiglio presso Chronic Airway Therapeutics
Profilo
Michael P.
Silvon is currently a Director at Chronic Airway Therapeutics.
Previously, he held the position of Vice President-Planning & Development at Inotiv, Inc. He was also the General Manager at BAS Evansville, Inc. from 2000 to 2002.
Additionally, he served as Vice President-Sales & Marketing at Hi-Port, Inc. and as Regional Business Manager-Americas-Fine Chemicals at Zeneca, Inc. Silvon received his undergraduate degree from Loyola University of Chicago, his MBA from Sacred Heart University, Inc., and his doctorate from the University of Vermont.
Posizioni attive di Michael P. Silvon
| Società | Posizione | Inizio |
|---|---|---|
Chronic Airway Therapeutics
 Chronic Airway Therapeutics BiotechnologyHealth Technology Chronic Airway Therapeutics develops treatments for chronic respiratory diseases. The private company is based in Kew East, Australia. The CEO of the Australian company is Mitchell Glass. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Michael P. Silvon
| Società | Posizione | Fine |
|---|---|---|
| BAS Evansville, Inc. | Corporate Officer/Principal | 01/01/2002 |
| Zeneca, Inc. | Corporate Officer/Principal | - |
| Hi-Port, Inc. | Vendite & Marketing | - |
| INOTIV, INC. | Corporate Officer/Principal | - |
Formazione di Michael P. Silvon
| Loyola University of Chicago | Undergraduate Degree |
| Sacred Heart University, Inc. | Masters Business Admin |
| University of Vermont | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| INOTIV, INC. | Commercial Services |
| Aziende private | 4 |
|---|---|
| BAS Evansville, Inc. | |
| Hi-Port, Inc. | |
| Zeneca, Inc. | |
Chronic Airway Therapeutics
Chronic Airway Therapeutics BiotechnologyHealth Technology Chronic Airway Therapeutics develops treatments for chronic respiratory diseases. The private company is based in Kew East, Australia. The CEO of the Australian company is Mitchell Glass. | Health Technology |
- Borsa valori
- Insiders
- Michael P. Silvon
